Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
44.02 (1y: +32%)
Market Cap 2.21 B P/E(ttm) 22.10
Enterprise Value 2.75 B P/B 3.50
CRL- NYSE (USA)
Charles River Laboratories International Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$44.02
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.175
CRL's Cash to Debt is ranked lower than
87% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. CRL: 0.175 )
CRL' s 10-Year Cash to Debt Range
Min: 0.04   Max: 1.05
Current: 0.18
0.04
1.05
Equity to Asset 0.194
CRL's Equity to Asset is ranked lower than
77% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. CRL: 0.194 )
CRL' s 10-Year Equity to Asset Range
Min: -0.41   Max: 0.41
Current: 0.19
-0.41
0.41
Interest Coverage 5.1
CRL's Interest Coverage is ranked lower than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. CRL: 5.1 )
CRL' s 10-Year Interest Coverage Range
Min: 2   Max: 27
Current: 5.1
2
27
F-Score: 6
Z-Score: 2.09
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 14.70
CRL's Operating margin (%) is ranked higher than
72% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. CRL: 14.70 )
CRL' s 10-Year Operating margin (%) Range
Min: -33.5   Max: 22.6
Current: 14.7
-33.5
22.6
Net-margin (%) 8.6
CRL's Net-margin (%) is ranked higher than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. CRL: 8.6 )
CRL' s 10-Year Net-margin (%) Range
Min: -38.8   Max: 13.1
Current: 8.6
-38.8
13.1
ROE (%) 16.2
CRL's ROE (%) is ranked higher than
80% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. CRL: 16.2 )
CRL' s 10-Year ROE (%) Range
Min: -49   Max: 20.8
Current: 16.2
-49
20.8
ROA (%) 6.1
CRL's ROA (%) is ranked higher than
63% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. CRL: 6.1 )
CRL' s 10-Year ROA (%) Range
Min: -24.2   Max: 10
Current: 6.1
-24.2
10
ROC (Joel Greenblatt) (%) 18.80
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.00 vs. CRL: 18.80 )
CRL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -48   Max: 53.1
Current: 18.8
-48
53.1
Revenue Growth (%) 6.2
CRL's Revenue Growth (%) is ranked higher than
68% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. CRL: 6.2 )
CRL' s 10-Year Revenue Growth (%) Range
Min: -13.9   Max: 8
Current: 6.2
-13.9
8
EBITDA Growth (%) 6.5
CRL's EBITDA Growth (%) is ranked lower than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.85 vs. CRL: 6.5 )
CRL' s 10-Year EBITDA Growth (%) Range
Min: -13.9   Max: 9.7
Current: 6.5
-13.9
9.7
EPS Growth (%) 3.7
CRL's EPS Growth (%) is ranked lower than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.90 vs. CRL: 3.7 )
CRL' s 10-Year EPS Growth (%) Range
Min: -10.6   Max: 20.4
Current: 3.7
-10.6
20.4
» CRL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CRL Guru Trades in Q2 2012

Jim Simons 567,309 sh (+90.75%)
Steven Cohen 49,537 sh (+37.16%)
Joel Greenblatt 42,112 sh (+25.2%)
PRIMECAP Management 528,700 sh (+12.46%)
John Rogers 3,127,355 sh (+3.74%)
David Dreman 1,055,935 sh (+0.24%)
Westport Asset Management 135,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2012

CRL Guru Trades in Q3 2012

Jim Simons 642,009 sh (+13.17%)
PRIMECAP Management 540,200 sh (+2.18%)
Westport Asset Management 135,000 sh (unchged)
David Dreman 1,021,334 sh (-3.28%)
John Rogers 2,858,725 sh (-8.59%)
Joel Greenblatt 30,668 sh (-27.18%)
Steven Cohen 19,822 sh (-59.99%)
» More
Q4 2012

CRL Guru Trades in Q4 2012

Robert Olstein 123,000 sh (New)
Paul Tudor Jones 6,100 sh (New)
Steven Cohen 25,199 sh (+27.13%)
Jim Simons 651,100 sh (+1.42%)
PRIMECAP Management 541,200 sh (+0.19%)
Westport Asset Management 155,000 sh (unchged)
David Dreman 997,472 sh (-2.34%)
John Rogers 2,743,925 sh (-4.02%)
Joel Greenblatt 9,794 sh (-68.06%)
» More
Q1 2013

CRL Guru Trades in Q1 2013

RS Investment Management 17,700 sh (New)
Jim Simons 1,443,409 sh (+121.69%)
Paul Tudor Jones 10,200 sh (+67.21%)
PRIMECAP Management 901,800 sh (+66.63%)
Robert Olstein 172,000 sh (+39.84%)
John Rogers 2,763,450 sh (+0.71%)
Westport Asset Management 155,000 sh (unchged)
Joel Greenblatt Sold Out
David Dreman 870,399 sh (-12.74%)
Steven Cohen 13,890 sh (-44.88%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.02%$37.47 - $45.79 $ 44.025%0
PRIMECAP Management 2013-03-31 Add 66.63%0.02%$37.47 - $45.79 $ 44.025%901800
Joel Greenblatt 2012-12-31 Reduce -68.06%0.06%$35.65 - $41.24 $ 44.0213%9794
Joel Greenblatt 2012-09-30 Reduce -27.18%0.03%$32.27 - $39.6 $ 44.0223%30668
Joel Greenblatt 2012-06-30 Add 25.2%0.02%$31.91 - $36.62 $ 44.0229%42112
Joel Greenblatt 2012-03-31 Reduce -49.74%0.11%$27.39 - $37.02 $ 44.0239%33635
PRIMECAP Management 2012-03-31 Add 125.26%0.01%$27.39 - $37.02 $ 44.0239%470112
Ray Dalio 2012-03-31 Sold Out 0.0038%$27.39 - $37.02 $ 44.0239%0
Arnold Van Den Berg 2011-12-31 Sold Out 0.09%$25.95 - $33.57 $ 44.0254%0
Joel Greenblatt 2011-12-31 Add 69.76%0.09%$25.95 - $33.57 $ 44.0254%66917
PRIMECAP Management 2011-12-31 Add 177.9%0.01%$25.95 - $33.57 $ 44.0254%208700
Ray Dalio 2011-12-31 Reduce -29.15%$25.95 - $33.57 $ 44.0254%8289
Joel Greenblatt 2011-09-30 Add 111.92%0.1%$28.5 - $42.05 $ 44.0226%39419
Ray Dalio 2011-09-30 New Buy0.01%$28.5 - $42.05 $ 44.0227%11700
George Soros 2011-09-30 Sold Out 0.0038%$28.5 - $42.05 $ 44.0226%0
Jean-Marie Eveillard 2011-09-30 Sold Out 0.0018%$28.5 - $42.05 $ 44.0226%0
Joel Greenblatt 2011-06-30 Reduce -20.11%0.05%$37.38 - $42.3 $ 44.0210%18601
Joel Greenblatt 2011-03-31 New Buy0.27%$35.54 - $39.39 $ 44.0217%23284
George Soros 2011-03-31 Reduce -71.49%$35.54 - $39.39 $ 44.0217%6700
David Dreman 2010-12-31 Add 91.48%0.38%$31.39 - $35.99 $ 44.0232%1098665
David Dreman 2010-09-30 Add 514.48%0.37%$28.25 - $35.6 $ 44.0239%573775
George Soros 2010-09-30 Add 142.27%0.01%$28.25 - $35.6 $ 44.0239%23500
PRIMECAP Management 2010-09-30 Reduce -25.98%$28.25 - $35.6 $ 44.0239%80900
Ron Baron 2010-06-30 Sold Out 0.48%$30.44 - $41.56 $ 44.0225%0
David Dreman 2010-06-30 New Buy0.08%$30.44 - $41.56 $ 44.0225%93375
George Soros 2010-06-30 Reduce -55.71%0.01%$30.44 - $41.56 $ 44.0225%9700
PRIMECAP Management 2010-06-30 Reduce -90.86%0.01%$30.44 - $41.56 $ 44.0225%109300
Jean-Marie Eveillard 2010-06-30 New Buy$30.44 - $41.56 $ 44.0225%9500
Arnold Van Den Berg 2010-03-31 New Buy0.1%$33.31 - $39.57 $ 44.0218%34565
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Charles River Laboratories International Inc

Robert Olstein’s Largest New Stock Picks
February 12, 2013
Robert Olstein - Robert Olstein’s Largest New Stock Picks
Robert Olstein, manager of the Olstein Funds, bought eight new stocks in the fourth quarter for his Olstein All-Cap Value Fund, the largest positions of which are: Ross Stores (ROST), Charles River Laboratories International (CRL) and Vishay Intertechnology (VSH). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 22.10
CRL's P/E(ttm) is ranked higher than
76% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.95 vs. CRL: 22.10 )
CRL' s 10-Year P/E(ttm) Range
Min: 8.55   Max: 510.25
Current: 22.1
8.55
510.25
P/B 3.50
CRL's P/B is ranked lower than
58% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. CRL: 3.50 )
CRL' s 10-Year P/B Range
Min: 0.78   Max: 9.44
Current: 3.5
0.78
9.44
P/S 1.80
CRL's P/S is ranked higher than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. CRL: 1.80 )
CRL' s 10-Year P/S Range
Min: 1.12   Max: 3.91
Current: 1.8
1.12
3.91
PFCF 12.20
CRL's PFCF is ranked higher than
71% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. CRL: 12.20 )
CRL' s 10-Year PFCF Range
Min: 8.88   Max: 907.57
Current: 12.2
8.88
907.57
EV-to-EBIT 16.7
CRL's EV-to-EBIT is ranked higher than
81% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. CRL: 16.7 )
CRL' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 75
Current: 16.7
7.3
75
Shiller P/E 25.4
CRL's Shiller P/E is ranked lower than
93% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.19 vs. CRL: 25.4 )
CRL' s 10-Year Shiller P/E Range
Min: 12.92   Max: 49.31
Current: 25.4
12.92
49.31

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 11.7
CRL's Price/Net Current Asset Value is ranked higher than
61% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. CRL: 11.7 )
CRL' s 10-Year Price/Net Current Asset Value Range
Min: 8.4   Max: 23.3
Current: 11.7
8.4
23.3
Price/Tangible Book 6.9
CRL's Price/Tangible Book is ranked higher than
80% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. CRL: 6.9 )
CRL' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 14.6
Current: 6.9
2.9
14.6
Price/DCF (Projected) 1.3
CRL's Price/DCF (Projected) is ranked higher than
81% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. CRL: 1.3 )
CRL' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 1.9
Current: 1.3
0.9
1.9
Price/Median PS Value 0.7
CRL's Price/Median PS Value is ranked higher than
54% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. CRL: 0.7 )
CRL' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.3
Current: 0.7
0.5
1.3
Price/Graham Number 2.6
CRL's Price/Graham Number is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. CRL: 2.6 )
CRL' s 10-Year Price/Graham Number Range
Min: 1.7   Max: 5
Current: 2.6
1.7
5
Earnings Yield (Greenblatt) 6.00
CRL's Earnings Yield (Greenblatt) is ranked higher than
83% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. CRL: 6.00 )
CRL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 13.7
Current: 6
1.3
13.7
Forward Rate of Return (Yacktman) 3.95
CRL's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. CRL: 3.95 )
CRL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.1   Max: 16
Current: 3.95
-1.1
16

Business Description

Charles River Laboratories International Inc. was incorporated in 1994. In 2000, it completed its initial public offering. The Company is a global provider of solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. It currently has two reporting segments: Research Models and Services (RMS) and Preclinical Services (PCS). Charles River has been supplying research models to the drug development industry since 1947. With approximately 150 different strains, it continues to maintain its position as the global leader in the production and sale of the most widely used rodent research model strains, principally genetically and virally defined purpose-bred rats and mice. The Company's RMS segment is comprised of Research Models, Research Model Services and other related products and services. It provides its rodent models to numerous customers around the world, including most pharmaceutical companies, a range of biotechnology companies, many government agencies, and hospitals and academic institutions. Research Model Services capitalize on the technologies and relationships developed through its research model business, and address the need among pharmaceutical and biotechnology companies to outsource the non-core aspects of their drug discovery activities. These services include those which are related to genetically defined research models for in-house research, as well as those services designed to implement efficacy screening protocols to improve the customer's drug evaluation process. The Company also offers two other categories of products and services within RMS - in vitro products and avian vaccine services. Its In Vitro business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. The company is the global leader for the supply of specific pathogen-free, or SPF, chickens and fertile chicken eggs. SPF chicken embryos are used by animal health companies as self-contained "bioreactors" for the manufacture of live viruses. The Company is a provider of preclinical services worldwide and offers particular expertise in the design, execution and reporting of general and specialty toxicology studies, especially those dealing with innovative therapies and biologicals. It currently provides preclinical services at multiple facilities located in the United States, Canada, Europe and Asia 'China'. It competes in the marketplace on the basis of quality, reputation, responsiveness, pricing, innovation, breadth of therapeutic and scientific expertise, timeliness and availability, supported by its professional bench strength in animal science and toxicology, global capabilities and strategically located facilities worldwide. With the exception of technology related to its in vitro testing business, including the Endosafe-PTS, and its pathology based software develo
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:RV6.Germany
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 
Ken Heebner Top Holdings: AAPL Is a Buy at $380 Jan 11 2012 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Aug 03 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Apr 29 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2009 
Charles River Laboratories International Reports Operating Results (10-Q) Aug 06 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial